Targeted therapy for pulmonary alveolar proteinosis: the time is now
- PMID: 35450922
- DOI: 10.1183/13993003.02971-2021
Targeted therapy for pulmonary alveolar proteinosis: the time is now
Conflict of interest statement
Conflict of interest: F. Bonella reports personal fees and non-financial support from Boehringer Ingelheim, Roche, BMS, Galapagos, Sanofi, Fujirebio and Savara, outside the submitted work. Conflict of interest: R. Borie reports personal fees and non-financial support from Boehringer Ingelheim, Roche, Sanofi and Savara, outside the submitted work.
Comment on
-
Methionine supplementation for multi-organ dysfunction in MetRS-related pulmonary alveolar proteinosis.Eur Respir J. 2022 Apr 21;59(4):2101554. doi: 10.1183/13993003.01554-2021. Print 2022 Apr. Eur Respir J. 2022. PMID: 34503986
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources